The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector
暂无分享,去创建一个
Long Chen | Chunmin Liang | Shuang Zhou | Ri-lun Li | Binbin Liu | Huiying Ma | Heng Hu | Yin‐kun Liu
[1] R. Strieter,et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2006, Cancer research.
[2] 寒川 延子. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes , 2006 .
[3] T. Yamano,et al. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Xiao Xiao,et al. Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase , 2005, Cell Research.
[5] Y. Kan,et al. Adeno-Associated Viral Vector Delivered Cardiac-Specific and Hypoxia-Inducible VEGF Expression in the Ischemic Mouse Hearts , 2022 .
[6] H. Kaufman,et al. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. , 2004, Cellular immunology.
[7] A. O’Garra,et al. Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.
[8] C. Piccirillo,et al. Cornerstone of peripheral tolerance: naturally occurring CD4+CD25+ regulatory T cells. , 2004, Trends in immunology.
[9] M. Huang,et al. Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity , 2004, Clinical Cancer Research.
[10] Y. Koyanagi,et al. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT , 2004, Cancer Gene Therapy.
[11] M. Moser,et al. CD4+ CD25+ Regulatory T Cells Control T Helper Cell Type 1 Responses to Foreign Antigens Induced by Mature Dendritic Cells In Vivo , 2003, The Journal of experimental medicine.
[12] S. Fan,et al. Long‐term expression of angiostatin suppresses metastatic liver cancer in mice , 2003, Hepatology.
[13] M. Huang,et al. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9 and IP-10/CXCL10 , 2003, Molecular Cancer.
[14] F. Ramsdell,et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.
[15] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[16] C. Martínez-A,et al. CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway. , 2003, Blood.
[17] H. Federoff,et al. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. , 2002, Cancer research.
[18] C. Cohen,et al. Roles of SLC/CCL21 and CCR7 in Human Kidney for Mesangial Proliferation, Migration, Apoptosis, and Tissue Homeostasis1 , 2002, The Journal of Immunology.
[19] T. Wagner,et al. Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice. , 2002, Anticancer research.
[20] Osamu Yoshie,et al. Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. , 2002, Immunity.
[21] M. Carson,et al. A Ligand for the Chemokine Receptor CCR7 Can Influence the Homeostatic Proliferation of CD4 T Cells and Progression of Autoimmunity1 , 2001, The Journal of Immunology.
[22] R. Strieter,et al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2001, Cancer research.
[23] Rolf M. Zinkernagel,et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.
[24] E. Shevach. Certified Professionals , 2001, The Journal of experimental medicine.
[25] J. Mulé,et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. , 2001, Cancer research.
[26] S. Fujita,et al. Enhancement of anti‐tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI‐1‐ligand chemokine and stromal cell–derived factor‐1αchemokine genes , 2001, International journal of cancer.
[27] T. Kakiuchi,et al. Mice Lacking Expression of the Chemokines Ccl21-Ser and Ccl19 (plt Mice) Demonstrate Delayed but Enhanced T Cell Immune Responses , 2001, The Journal of experimental medicine.
[28] Hyun Chul Lee,et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue , 2000, Nature.
[29] C. Caux,et al. Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms1 , 2000, The Journal of Immunology.
[30] R. Schreiber,et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.
[31] M. Burdick,et al. Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo1 , 2000, The Journal of Immunology.
[32] E. Wolf,et al. CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs , 1999, Cell.
[33] P. Lollini,et al. Specific and nonspecific immunity in the prevention of spontaneous tumours. , 1999, Immunology today.
[34] L. Williams,et al. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. , 1999, Blood.
[35] H. Broxmeyer,et al. CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors. , 1999, Cellular immunology.
[36] S. Hudak,et al. The CC Chemokine Receptor-7 Ligands 6Ckine and Macrophage Inflammatory Protein-3β Are Potent Chemoattractants for In Vitro- and In Vivo-Derived Dendritic Cells , 1999, The Journal of Immunology.
[37] P. Klenerman,et al. Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[38] L. Williams,et al. Mice Lacking Expression of Secondary Lymphoid Organ Chemokine Have Defects in Lymphocyte Homing and Dendritic Cell Localization , 1999, The Journal of experimental medicine.
[39] D. Erle,et al. Secondary Lymphoid-Tissue Chemokine (SLC) Stimulates Integrin α4β7-Mediated Adhesion of Lymphocytes to Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Under Flow , 1998, The Journal of Immunology.
[40] N. Copeland,et al. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] M. Baggiolini,et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7 , 1998, European journal of immunology.
[42] E. Butcher,et al. 6-C-kine (SLC), a Lymphocyte Adhesion-triggering Chemokine Expressed by High Endothelium, Is an Agonist for the MIP-3β Receptor CCR7 , 1998, The Journal of cell biology.
[43] H. Nomiyama,et al. A lymphocyte‐specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells , 1998, European journal of immunology.
[44] O. Yoshie,et al. Secondary Lymphoid-tissue Chemokine Is a Functional Ligand for the CC Chemokine Receptor CCR7* , 1998, The Journal of Biological Chemistry.
[45] J. Cyster,et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] D. Erle,et al. Secondary lymphoid-tissue chemokine (SLC) stimulates integrin alpha 4 beta 7-mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow. , 1998, Journal of immunology.
[47] Andrew Freese,et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector , 1998, Gene Therapy.
[48] M. Klemsz,et al. Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. , 1997, Journal of immunology.
[49] M. Ridanpää,et al. Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13* , 1997, The Journal of Biological Chemistry.
[50] J. Bluestone,et al. Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy , 1997, The Journal of experimental medicine.
[51] B. Byrne,et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[52] S. Burdach,et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.
[53] D. Goeddel,et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. , 1996, Human gene therapy.
[54] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[55] Donald W. Pfaff,et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.